Search results
Results from the WOW.Com Content Network
Solifenacin, sold as the brand name Vesicare [a] among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). [1] [2] It may help with incontinence, urinary frequency, and urinary urgency. [3] Benefits appear similar to other medications in the class. [4] It is taken by mouth. [1]
Vibegron, sold under the brand name Gemtesa, is a medication for the treatment of overactive bladder. [1] [5] [6] Vibegron is a selective beta-3 adrenergic receptor agonist. [1] The most common side effects include headache, urinary tract infection, common cold, diarrhea, nausea, and upper respiratory tract infection. [5]
Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. [5] Its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine. [6] It is taken by mouth. [5] Common side effects include high blood pressure, headaches, and urinary tract infections. [5]
Prepare for potential side effects. Taking metformin may cause unpleasant side effects like diarrhea, nausea, upset stomach and, in rare cases, lactic acidosis. Don’t double up on metformin if ...
These side effects might be common, but there are things you can do if they’re impacting your daily life. 6 Common Side Effects from Taking a GLP-1 Medication—and How to Manage Them Skip to ...
Oxybutynin, sold under the brand name Ditropan among others, is an anticholinergic medication primarily used to treat overactive bladder.It is widely considered a first-line therapy for overactive bladder due to its well-studied side effect profile, broad applicability, and continued efficacy over long periods of time.
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). [2] It was approved by the European Medicines Agency in April 2007, [3] the US Food and Drug Administration on October 31, 2008 [4] and Health Canada on February 9, 2012.
Darifenacin (trade name Enablex in United States and Canada, Emselex in the European Union) is a medication used to treat urinary incontinence due to an overactive bladder. [1] [2] [3] It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis.